Compare funds
Pick up to 10 funds. Compare funds from the same category for a fair reading.
Growth of ₹10,000
Basics
| Nippon India BSE Sensex Next 30 ETF | Nippon India Nifty Pharma ETF | |
|---|---|---|
| Category | Equity ETFs | Equity ETFs |
| Plan | Direct | Direct |
| Fund house | Nippon India | Nippon India |
| NAV | ₹42.8163 | ₹29.1863 |
| NAV date | 20 Nov 2026 | 20 Nov 2026 |
| History | 1.4 years | 5.4 years |
| Expense ratio | 0.2% | 0.2% |
| Stars | Not rated | Not rated |
| Growth Score | — | — |
Returns
| Nippon India BSE Sensex Next 30 ETF | Nippon India Nifty Pharma ETF | |
|---|---|---|
| 1 month | +7.77% | +10.82% |
| 3 months | −1.30% | +7.43% |
| 6 months | +1.74% | +14.54% |
| YTD | +5.05% | +25.40% |
| 1 year | +6.35% | +25.57% |
| 3 years (CAGR) | — | +22.02% |
| 5 years (CAGR) | — | +16.60% |
| 10 years (CAGR) | — | — |
| Since launch | +8.51% | +14.02% |
Risk
| Nippon India BSE Sensex Next 30 ETF | Nippon India Nifty Pharma ETF | |
|---|---|---|
| Volatility | — | 15.0% |
| Downside volatility | — | 9.0% |
| Sharpe | — | 1.04 |
| Sortino | — | 1.72 |
| Calmar | — | 1.33 |
| Return / risk | — | 1.47 |
| Deepest fall | −12.04% | −20.98% |
| Days to recover | — | 136 |
| Below its high | −2.49% | −1.75% |
Against benchmark
| Nippon India BSE Sensex Next 30 ETF | Nippon India Nifty Pharma ETF | |
|---|---|---|
| Alpha | — | +0.00% |
| Beta | — | 1.00 |
| R² | — | 100.0% |
| Up capture | — | 100.0% |
| Down capture | — | 100.0% |
| Tracking error | — | 0.0% |
| Information ratio | — | — |
| Treynor | — | 0.14 |
Consistency
| Nippon India BSE Sensex Next 30 ETF | Nippon India Nifty Pharma ETF | |
|---|---|---|
| Best 1-year | +16.89% | +65.21% |
| Middle 1-year | +7.84% | +13.46% |
| Worst 1-year | −3.79% | −15.30% |
| 1-year periods with a loss | 9.9% | 25.8% |
| Middle 3-year | — | +20.51% |
| Positive months | — | 61.1% |
| Best day | +2.90% | +3.64% |
| Worst day | −3.39% | −4.03% |
| Worst 5% day | −1.46% | −1.62% |
| Positive days | 54.5% | 54.4% |
| NAVs a year | 248 | 248 |
SIP of ₹10,000 a month
| Nippon India BSE Sensex Next 30 ETF | Nippon India Nifty Pharma ETF | |
|---|---|---|
| 5-year XIRR | — | +20.60% |
| 5-year value | — | ₹10,11,738 |
| 3-year XIRR | — | +19.58% |
| 1-year XIRR | +7.92% | +34.31% |
Holdings overlap i
| Nippon India BSE Sensex Next 30 ETF | Nippon India Nifty Pharma ETF | |
|---|---|---|
| Nippon India BSE Sensex Next 30 ETF | — | 12% |
| Nippon India Nifty Pharma ETF | 12% | — |
Share of money in the same stocks, by weight. Above 50% means much of one fund repeats the other.
Held by all of them
| Stock | Nippon India BSE Sensex Next 30 ETF | Nippon India Nifty Pharma ETF |
|---|---|---|
| Divi's Laboratories Limited | 5.06% | 12.28% |
| Dr. Reddy's Laboratories Limited | 3.36% | 8.15% |
| Cipla Limited | 3.19% | 7.67% |
Sectors and company size
| Nippon India BSE Sensex Next 30 ETF | Nippon India Nifty Pharma ETF | |
|---|---|---|
| Large companies | 86.6% | 45.3% |
| Mid companies | 13.3% | 47.1% |
| Small companies | — | 7.6% |
| Top 10 holdings | 44.5% | 78.6% |
| Largest sector | Automobiles 18% | Pharmaceuticals & Biotechnology 100% |